Donald Bren School of Information and Computer Sciences, University of California, Irvine, Irvine, California.
Johns Hopkins University School of Medicine, Baltimore, Maryland.
Int J Radiat Oncol Biol Phys. 2024 Aug 1;119(5):1368-1378. doi: 10.1016/j.ijrobp.2024.02.038. Epub 2024 Mar 10.
To assess delays in treatment initiation of chemoradiation or radiation alone for patients with advanced stage cervical cancer in Botswana.
Females with locally advanced cervical cancer (stages IB2-IVB) were prospectively enrolled in an observational cohort study from 2015 to 2019. We evaluated delays at 30, 60, 90, 120, 150, and 180 or greater days between the date of diagnosis and treatment initiation. Factors associated with overall survival were modeled with multivariable Cox proportional hazards regression (aHR). Associations between delays in cervical cancer treatment initiation were evaluated via univariable logistic regression.
Among the 556 patients included (median age = 47.9 years), 386 (69.4%) were females living with HIV with a median CD4 count of 448.0 cells/μL (IQR, 283.0-647.5 cells/μL) at diagnosis. Most patients had stages 2 (38.1%) or 3 (34.5%) cervical cancer. Early-stage patients experienced longer delays in treatment initiation compared to late-stage patients (P = .033). Early-stage patients with delays ≥90 days and pathology diagnosis between 2016 and 2019 (aHR, 0.34; P < .001) versus <90 days had a decreased risk of mortality, and those with delays ≥90 days and pathology diagnosis before 2016 (aHR, 5.67; P = .022) versus <90 days had an increased risk of mortality. Late-stage patients with delays ≥120 days and pathology diagnosis between 2018 and 2019 (aHR, 1.98; P = .025) versus <120 days had an increased risk of mortality. Early-stage patients with pathology diagnosis between 2016 and 2019 (odds ratio, 2.32; P = .043) versus before 2016 were more likely to experience delays ≥90 days, and late-stage patients who traveled >100 km to the treatment facility (odds ratio, 2.83; P < .001) versus <100 km were more likely to experience delays ≥120 days.
Delays in care are common in Botswana, particularly for those living farther from the treatment clinic and at advanced stages. This paper is among the first to show an association between treatment delays and worsened overall survival at advanced stages of cervical cancer, highlighting the need for interventions to help patients receive timely care in global settings.
评估博茨瓦纳晚期宫颈癌患者接受放化疗或单纯放疗治疗的起始延迟。
2015 年至 2019 年期间,前瞻性纳入了局部晚期宫颈癌(IB2-IVB 期)女性患者,进行观察性队列研究。我们评估了自诊断之日起 30、60、90、120、150 和 180 天或以上治疗开始之间的延迟。使用多变量 Cox 比例风险回归(aHR)对与总生存相关的因素进行建模。通过单变量逻辑回归评估宫颈癌治疗起始延迟之间的关联。
在 556 名纳入的患者中(中位年龄=47.9 岁),386 名(69.4%)为女性,HIV 阳性,诊断时中位 CD4 计数为 448.0 个细胞/μL(IQR,283.0-647.5 个细胞/μL)。大多数患者患有 2 期(38.1%)或 3 期(34.5%)宫颈癌。与晚期患者相比,早期患者的治疗开始延迟时间更长(P=0.033)。延迟≥90 天且病理诊断在 2016 年至 2019 年之间的早期患者(aHR,0.34;P<0.001)与延迟<90 天的患者相比,死亡风险降低,而延迟≥90 天且病理诊断在 2016 年之前的患者(aHR,5.67;P=0.022)与延迟<90 天的患者相比,死亡风险增加。延迟≥120 天且病理诊断在 2018 年至 2019 年之间的晚期患者(aHR,1.98;P=0.025)与延迟<120 天的患者相比,死亡风险增加。延迟≥90 天的早期患者,与 2016 年之前相比,2016 年至 2019 年之间的病理诊断(比值比,2.32;P=0.043)更有可能发生延迟,而晚期患者到治疗机构的旅行距离>100 公里(比值比,2.83;P<0.001)与<100 公里相比,更有可能发生延迟≥120 天。
在博茨瓦纳,护理延迟很常见,特别是对于那些离治疗诊所更远和处于晚期的患者。本文是首批表明宫颈癌晚期治疗延迟与总生存恶化之间存在关联的论文之一,这凸显了在全球范围内需要干预措施来帮助患者及时获得护理。